Salt Lake City, Utah, USA, May 18, 2016 – Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry. When the Electro Pulmonary Nodule (EPN) Scan was administered to patients with lung nodules suspicious for cancer, the scan demonstrated results consistent with earlier research performed at Johns Hopkins and published in the Journal of Thoracic Oncology. The non-invasive test correctly identified 23 out of 27, or 85% of patients where malignancy was confirmed by tissue biopsy. More results are expected soon, as the EPN Scan has been administered to more than 170 patients in Europe and over 100 of these are enrolled in the registry. Other research is underway at eight cancer centers in the US and four in Asia.
“The key to improved survival is understanding the risk associated with a suspicious pulmonary nodule. It’s heartening to see such positive results coming from leading European interventional pulmonologists. They are pioneers focused on immediate evaluation of indeterminate lung nodules. Compared with the standard of care, we believe that the EPN Scan can increase the time available for treatment and may ultimately save lives,” said Steven Eror, President and CEO of ProLungdx.
The EPN Scan uses its novel mass averaging bioconductance technology to evaluate patients who discover lung nodules incidentally or by lung cancer screening. As the low-dose computed tomography (LDCT) screen becomes widespread, risk stratification tools, such as ProLungdx’s EPN Scan, will be essential to aiding physicians to evaluate the risk of cancer while treatment options are still available.
ProLungdx is a privately held, US-based medical technology company that develops, manufactures and sells non-invasive medical technology to aid in the early detection and diagnosis of lung cancer. The EPN Scan is approved for sale in the European Economic Area and is for investigational use only in the US.
This release may contain forward-looking statements as well as historical information. Forward-looking statements, which are included in accordance with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, may involve risks, uncertainties and other factors that may cause ProLungdx’s actual results and performance in future periods to be materially different from any future results or performance suggested by the forward-looking statements in this release. These risks and uncertainties include, without limitation, the risks that the EPN Scan will not perform as well in future clinical trials or real world application as suggested by the sample discussed in this release, that the EPN Scan will not be adopted by doctors and hospitals in Europe or the U.S. for a number of reasons, including the adoption of competing technologies or concerns about the EPN Scan, and that the EPN Scan will not receive marketing approval by the FDA and other regulatory authorities. Forward-looking statements in this press release speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any changes in company expectations or results or any change in events.
To utilize the ProLungdx EPN Scan, please contact the Company through the listed information.
For more information, contact:
C. Lindsay McSweeney